Nuformix (LSE:NFX) Operating Margin %: 0.00% (As of Mar. 2026)


What is Nuformix Operating Margin %?

Nuformix LSE:NFX -8.85% Operating Margin % is 0.00% as of Mar. 2026. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Nuformix ranks worse than 105820% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Nuformix's Operating Income for the six months ended in Mar. 2026 was £-0.35 Mil. Nuformix's Revenue for the six months ended in Mar. 2026 was £0.00 Mil. Therefore, Nuformix's Operating Margin % for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Nuformix's Operating Margin % or its related term are showing as below:


LSE:NFX's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.89
* Ranked among companies with meaningful Operating Margin % only.

Nuformix's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Nuformix's Operating Income for the six months ended in Mar. 2026 was £-0.35 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was £-0.63 Mil.


Nuformix  (LSE:NFX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Nuformix Operating Margin % Related Terms


Nuformix Operating Margin % Historical Data

* Premium members only.

The historical data trend for Nuformix's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuformix Operating Margin % Chart

Nuformix Annual Data
Trend Dec15 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Sep24 Sep25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -700.51 -2,540.00 0.00 0.00 0.00

Nuformix Semi-Annual Data
Dec15 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LSE:NFX vs VRTX, REGN, ALNY: Operating Margin % Comparison

For the Biotechnology subindustry, Nuformix's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuformix Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuformix's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Nuformix's Operating Margin % falls into.



Nuformix Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Nuformix's Operating Margin % for the fiscal year that ended in Sep. 2025 is calculated as

Operating Margin %=Operating Income (A: Sep. 2025 ) / Revenue (A: Sep. 2025 )
=-0.661 / 0
= %

Nuformix's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-0.347 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Nuformix (LSE:NFX) has a Operating Margin % of 0.00% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Nuformix and its competitors. According to the industry distribution chart, Nuformix ranks #999999 out of 945 companies in the Biotechnology industry.
Is Nuformix's Operating Margin % too high?
Nuformix's current Operating Margin % is 0.00%. Based on the distribution chart, Nuformix ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Nuformix's Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nuformix ranks #999999 out of 945 companies for Operating Margin %. This places Nuformix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Nuformix and its competitors. Nuformix's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuformix stock overvalued right now?
Nuformix (LSE:NFX) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Nuformix (LSE:NFX), the current Operating Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nuformix Business Description

Other Exchanges 1RT:Germany
Address C/O Arch Law Limited, 8 Bishopsgate, Huckletree Bishopsgate, London, GBR, EC2N 4BQ
Nuformix PLC is a pharmaceutical development company. It operates in pharmaceutical development, targeting unmet medical needs in fibrosis and oncology through drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.